Placental Growth Factor for the Prediction of Adverse Outcomes in Patients with Suspected Preeclampsia or Intrauterine Growth Restriction

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Sibiude, Jeanne ^a   Guibourdenche, Jean ^a,b,c   Dionne, Marie Danielle ^a,d   Le Ray, Camille ^a,b,c,e   Anselem, Olivia ^a,b,c   Serreau, Raphaël ^a   Goffinet, François ^a,b,c,e   Tsatsaris, Vassilis ^a,b,c  

^a APHP Paris Descartes University ^*  (France)

^b PremUp Foundation   (France)

^c DHU Risks and Pregnancy   (France)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLACENTAL GROWTH FACTOR;

ADULT; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; BIRTH WEIGHT; CESAREAN SECTION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FETUS DEATH; GESTATIONAL AGE; HELLP SYNDROME; HUMAN; INTRAUTERINE GROWTH RETARDATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANCY OUTCOME; PREGNANCY TERMINATION; RECEIVER OPERATING CHARACTERISTIC; SMALL FOR DATE INFANT; STILLBIRTH; VAGINAL DELIVERY;

ADULT; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; FEMALE; FETAL GROWTH RETARDATION; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; LONGITUDINAL STUDIES; MODELS, STATISTICAL; ODDS RATIO; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY PROTEINS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84870334704     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050208     Document Type: Article

References (42)

1. Duley L, (2009) The global impact of pre-eclampsia and eclampsia. Semin Perinatol 33: 130-137.
2. Wallis AB, Saftlas AF, Hsia J, Atrash HK, (2008) Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens 21: 521-526.
3. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF, (2006) WHO analysis of causes of maternal death: a systematic review. Lancet 367: 1066-1074.
4. Dekker G, Sibai B, (2001) Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet 357: 209-215.
5. Belghiti J, Kayem G, Tsatsaris V, Goffinet F, Sibai BM, et al. (2011) Benefits and risks of expectant management of severe preeclampsia at less than 26 weeks gestation: the impact of gestational age and severe fetal growth restriction. Am J Obstet Gynecol 205: 465 e461-466.
6. Haddad B, Sibai BM, (2009) Expectant management in pregnancies with severe pre-eclampsia. Semin Perinatol 33: 143-151.
7. Ganzevoort W, Rep A, de Vries JI, Bonsel GJ, Wolf H, (2006) Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. Am J Obstet Gynecol 195: 495-503.
8. Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJ, (1990) Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: a randomized controlled trial. Obstet Gynecol 76: 1070-1075.
9. Sibai BM, (2003) Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 102: 181-192.
10. Sibai BM, (2011) Evaluation and management of severe preeclampsia before 34 weeks' gestation. Am J Obstet Gynecol 205: 191-198.
11. Thangaratinam S, Ismail KM, Sharp S, Coomarasamy A, Khan KS, (2006) Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. Bjog 113: 369-378.
12. Thangaratinam S, Coomarasamy A, O'Mahony F, Sharp S, Zamora J, et al. (2009) Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review. BMC Med 7: 10.
13. Chien PF, Arnott N, Gordon A, Owen P, Khan KS, (2000) How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. Bjog 107: 196-208.
14. Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, et al. (2007) Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 196: 326 e321-313.
15. Maulik D, Mundy D, Heitmann E, Maulik D, (2010) Evidence-based approach to umbilical artery Doppler fetal surveillance in high-risk pregnancies: an update. Clin Obstet Gynecol 53: 869-878.
16. Stamilio DM, Sehdev HM, Morgan MA, Propert K, Macones GA, (2000) Can antenatal clinical and biochemical markers predict the development of severe preeclampsia? Am J Obstet Gynecol 182: 589-594.
17. von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, et al. (2011) Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 377: 219-227.
18. Hall DR, Odendaal HJ, Kirsten GF, Smith J, Grove D, (2000) Expectant management of early onset, severe pre-eclampsia: perinatal outcome. Bjog 107: 1258-1264.
19. Urato AC, Bond B, Craigo SD, Norwitz ER, Paulus JK, et al. (2011) Admission uric acid levels and length of expectant management in preterm preeclampsia. J Perinatol.
20. Sibai B, Dekker G, Kupferminc M, (2005) Pre-eclampsia. Lancet 365: 785-799.
21. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, et al. (2003) Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 88: 5555-5563.
22. Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, et al. (2009) Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria. Hypertens Pregnancy 28: 95-108.
23. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, et al. (2005) Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 90: 4895-4903.
24. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683.
25. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, et al. (2012) Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125: 911-919.
26. Chitty LS, Altman DG, Henderson A, Campbell S, (1994) Charts of fetal size: 2. Head measurements. Br J Obstet Gynaecol 101: 35-43.
27. Acog practice bulletin. Number 33 j (2002) Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 99: 159-167.
28. Lubchenco LO, Hansman C, Dressler M, Boyd E, (1963) Intrauterine Growth as Estimated from Liveborn Birth-Weight Data at 24 to 42 Weeks of Gestation. Pediatrics 32: 793-800.
29. Knudsen U, Kronborg C, Dadelszen Pv, Kupfer K, Lee S-W, et al. (2012) A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertension 2: 8-15.
30. Palm M, Basu S, Larsson A, Wernroth L, Akerud H, et al. (2011) A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy. Acta Obstet Gynecol Scand 90: 1244-1251.
31. StataCorporation. (2009) Stata 11.0 for Windows. College Station, Texas: Stata Corporation.
32. Erez O, Romero R, Espinoza J, Fu W, Todem D, et al. (2008) The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 21: 279-287.
33. Quant H, Arden D, Takoudes T, Rana S, (2012) Angiogenic Factors and Pregnant Woman with New Onset Seizures. Hypertens Pregnancy.
34. Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, et al. (2006) Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol 194: 551-556.
35. Young B, Levine RJ, Salahuddin S, Qian C, Lim KH, et al. (2011) The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 23: 366-370.
36. Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH, (2010) Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol 35: 662-670.
37. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, et al. (2009) A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 22: 1021-1038.
38. Woodham PC, Brittain JE, Baker AM, Long DL, Haeri S, et al. (2011) Midgestation maternal serum 25-hydroxyvitamin D level and soluble fms-like tyrosine kinase 1/placental growth factor ratio as predictors of severe preeclampsia. Hypertension 58: 1120-1125.
39. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ, (2010) Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 122: 478-487.
40. Shokry M, Bedaiwy MA, Fathalla MM, Alsemary A, Elwakil S, et al. (2010) Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia. Acta Obstet Gynecol Scand 89: 143-146.
41. Romero R, Nien JK, Espinoza J, Todem D, Fu W, et al. (2008) A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 21: 9-23.
42. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, et al. (2011) Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 24: 1187-1207.